BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Brøchner CB, Johansen JS, Larsen LA, Bak M, Mikkelsen HB, Byskov AG, Andersen CY, Møllgård K. YKL-40 is differentially expressed in human embryonic stem cells and in cell progeny of the three germ layers. J Histochem Cytochem 2012;60:188-204. [PMID: 22140133 DOI: 10.1369/0022155411433331] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Qi R, Jin X, Shi H, Wang C, Li H, Shi X. Effect of laparoscopic splenectomy on portal vein thrombosis and serum YKL-40 in patients with cirrhotic portal hypertension. Annals of Hepatology 2019;18:898-901. [DOI: 10.1016/j.aohep.2019.06.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Li L, Fan J, Li D, Liu Y, Shrestha P, Zhong C, Xia X, Huang X. Influence of YKL-40 gene RNA interference on the biological behaviors of endometrial cancer HEC-1A cells. Oncol Lett 2018;16:1777-84. [PMID: 30008865 DOI: 10.3892/ol.2018.8814] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Kjaergaard AD, Johansen JS, Nordestgaard BG, Bojesen SE. Genetic variants in CHI3L1 influencing YKL-40 levels: resequencing 900 individuals and genotyping 9000 individuals from the general population. J Med Genet 2013;50:831-7. [PMID: 24062521 DOI: 10.1136/jmedgenet-2013-101908] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
4 Brøchner CB, Møllgård K. SSEA-4 and YKL-40 positive progenitor subtypes in the subventricular zone of developing human neocortex. Glia 2016;64:90-104. [PMID: 26295543 DOI: 10.1002/glia.22905] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
5 Peng H, Su Q, Lin ZC, Zhu XH, Peng MS, Lv ZB. Potential suppressive effects of theophylline on human rectal cancer SW480 cells in vitro by inhibiting YKL-40 expression. Oncol Lett 2018;15:7403-8. [PMID: 29731892 DOI: 10.3892/ol.2018.8220] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
6 Sørensen AK, Holmgaard DB, Mygind LH, Johansen J, Pedersen C. Neutrophil-to-lymphocyte ratio, calprotectin and YKL-40 in patients with chronic obstructive pulmonary disease: correlations and 5-year mortality - a cohort study. J Inflamm (Lond) 2015;12:20. [PMID: 25908927 DOI: 10.1186/s12950-015-0064-5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
7 Kornblit B, Hellemann D, Munthe-Fog L, Bonde J, Strøm JJ, Madsen HO, Johansen JS, Garred P. Plasma YKL-40 and CHI3L1 in systemic inflammation and sepsis-experience from two prospective cohorts. Immunobiology 2013;218:1227-34. [PMID: 23706599 DOI: 10.1016/j.imbio.2013.04.010] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
8 Tarpgaard LS, Guren TK, Glimelius B, Christensen IJ, Pfeiffer P, Kure EH, Sorbye H, Ikdahl T, Yilmaz M, Johansen JS, Tveit KM. Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII Study. PLoS One 2014;9:e87746. [PMID: 24498368 DOI: 10.1371/journal.pone.0087746] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
9 Krogh M, Christensen I, Bouwhuis M, Johansen JS, Nørgaard P, Schmidt H, Hansson J, Suciu S, Eggermont AM, Bastholt L; Nordic Melanoma Group and EORTC Melanoma Group. Prognostic and predictive value of YKL-40 in stage IIB-III melanoma. Melanoma Res 2016;26:367-76. [PMID: 27076041 DOI: 10.1097/CMR.0000000000000237] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 4.8] [Reference Citation Analysis]
10 Cheong Y, Sadek KH, Bruce KD, Macklon N, Cagampang FR. Diet-induced maternal obesity alters ovarian morphology and gene expression in the adult mouse offspring. Fertil Steril 2014;102:899-907. [PMID: 25063726 DOI: 10.1016/j.fertnstert.2014.06.015] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
11 Brøchner CB, Holst CB, Møllgård K. Outer brain barriers in rat and human development. Front Neurosci 2015;9:75. [PMID: 25852456 DOI: 10.3389/fnins.2015.00075] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 5.9] [Reference Citation Analysis]
12 Hansen JW, Thomsen SF, Porsbjerg C, Rasmussen LM, Harmsen L, Johansen JS, Backer V. YKL-40 and genetic status of CHI3L1 in a large group of asthmatics. Eur Clin Respir J 2015;2:25117. [PMID: 26672955 DOI: 10.3402/ecrj.v2.25117] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
13 Boisen MK, Holst CB, Consalvo N, Chinot OL, Johansen JS. Plasma YKL-40 as a biomarker for bevacizumab efficacy in patients with newly diagnosed glioblastoma in the phase 3 randomized AVAglio trial. Oncotarget 2018;9:6752-62. [PMID: 29467925 DOI: 10.18632/oncotarget.22886] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
14 Boisen MK, Madsen CV, Dehlendorff C, Jakobsen A, Johansen JS, Steffensen KD. The Prognostic Value of Plasma YKL-40 in Patients With Chemotherapy-Resistant Ovarian Cancer Treated With Bevacizumab. Int J Gynecol Cancer 2016;26:1390-8. [DOI: 10.1097/igc.0000000000000798] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
15 Palmquist C, Dehlendorff C, Calatayud D, Hansen CP, Hasselby JP, Johansen JS. Prediction of Unresectability and Prognosis in Patients Undergoing Surgery on Suspicion of Pancreatic Cancer Using Carbohydrate Antigen 19-9, Interleukin 6, and YKL-40. Pancreas 2020;49:53-61. [PMID: 31856080 DOI: 10.1097/MPA.0000000000001466] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
16 Nøjgaard C, Johansen JS, Bjerregaard P, Bojesen SE, Becker U. Plasma YKL-40 in Inuit and Danes. Alcohol Alcohol 2015;50:11-7. [PMID: 25332349 DOI: 10.1093/alcalc/agu072] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
17 Swaminathan G, Shigna A, Kumar A, Byroju VV, Durgempudi VR, Dinesh Kumar L. RNA Interference and Nanotechnology: A Promising Alliance for Next Generation Cancer Therapeutics. Front Nanotechnol 2021;3:694838. [DOI: 10.3389/fnano.2021.694838] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
18 Du C, Yang Y, Lin Y, Yang J. Expression and mechanism of BRP-39 in bleomycin-induced pulmonary fibrosis in rat. Cell Biochem Biophys 2014;70:251-7. [PMID: 24659093 DOI: 10.1007/s12013-014-9889-4] [Reference Citation Analysis]
19 Rondeau G, Abedinpour P, Desai P, Baron VT, Borgstrom P, Welsh J. Effects of different tissue microenvironments on gene expression in breast cancer cells. PLoS One 2014;9:e101160. [PMID: 25004123 DOI: 10.1371/journal.pone.0101160] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
20 Roslind A, Palle C, Johansen JS, Christensen IJ, Nielsen HJ, Mosgaard BJ. Prognostic utility of serum YKL-40 in patients with cervical cancer. Scand J Clin Lab Invest 2020;80:687-93. [PMID: 33186077 DOI: 10.1080/00365513.2020.1846209] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Rinnov AR, Rathcke CN, Bonde L, Vilsbøll T, Knop FK. Plasma YKL-40 during pregnancy and gestational diabetes mellitus. J Reprod Immunol 2015;112:68-72. [PMID: 26301577 DOI: 10.1016/j.jri.2015.06.092] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
22 Komi DE, Kazemi T, Bussink AP. New Insights Into the Relationship Between Chitinase-3-Like-1 and Asthma. Curr Allergy Asthma Rep 2016;16:57. [PMID: 27438466 DOI: 10.1007/s11882-016-0637-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
23 Bjørnbak C, Brøchner CB, Larsen LA, Johansen JS, Møllgård K. Brain barriers and a subpopulation of astroglial progenitors of developing human forebrain are immunostained for the glycoprotein YKL-40. J Histochem Cytochem 2014;62:369-88. [PMID: 24595665 DOI: 10.1369/0022155414528514] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
24 Vocka M, Langer D, Fryba V, Petrtyl J, Hanus T, Kalousova M, Zima T, Petruzelka L. Novel serum markers HSP60, CHI3L1, and IGFBP-2 in metastatic colorectal cancer. Oncol Lett 2019;18:6284-92. [PMID: 31788106 DOI: 10.3892/ol.2019.10925] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
25 Holmgaard DB, Mygind LH, Titlestad IL, Madsen H, Pedersen SS, Johansen JS, Pedersen C. Plasma YKL-40 and all-cause mortality in patients with chronic obstructive pulmonary disease. BMC Pulm Med 2013;13:77. [PMID: 24373580 DOI: 10.1186/1471-2466-13-77] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
26 Yan J, Shen P, Zheng J, Liu M. Clinical correlation between serum YKL-40 protein level and recurrence of non-muscle invasive bladder cancer. Ann Transl Med 2015;3:354. [PMID: 26807409 DOI: 10.3978/j.issn.2305-5839.2015.11.22] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Gybel-Brask D, Høgdall E, Johansen J, Christensen IJ, Skibsted L. Serum YKL-40 and uterine artery Doppler -- a prospective cohort study, with focus on preeclampsia and small-for-gestational-age. Acta Obstet Gynecol Scand 2014;93:817-24. [PMID: 24861484 DOI: 10.1111/aogs.12432] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
28 Gybel-Brask D, Johansen JS, Christiansen IJ, Skibsted L, Høgdall EV. Serum YKL-40 and gestational diabetes - an observational cohort study. APMIS 2016;124:770-5. [PMID: 27457220 DOI: 10.1111/apm.12573] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
29 Mygind ND, Iversen K, Køber L, Goetze JP, Nielsen H, Boesgaard S, Bay M, Johansen JS, Nielsen OW, Kirk V, Kastrup J. The inflammatory biomarker YKL-40 at admission is a strong predictor of overall mortality. J Intern Med 2013;273:205-16. [PMID: 23140269 DOI: 10.1111/joim.12006] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
30 Schultz NA, Christensen IJ, Werner J, Giese N, Jensen BV, Larsen O, Bjerregaard JK, Pfeiffer P, Calatayud D, Nielsen SE. Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer. PLoS One. 2013;8:e67059. [PMID: 23840582 DOI: 10.1371/journal.pone.0067059] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
31 Li LL, Fan JT, Li DH, Liu Y. Effects of a Small Interfering RNA Targeting YKL-40 Gene on the Proliferation and Invasion of Endometrial Cancer HEC-1A Cells. Int J Gynecol Cancer 2016;26:1190-5. [PMID: 27465891 DOI: 10.1097/IGC.0000000000000774] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
32 Harutyunyan M, Johansen JS, Mygind ND, Reuter SB, Kastrup J. Serum YKL-40 for monitoring myocardial ischemia after revascularization in patients with stable coronary artery disease. Biomark Med 2014;8:977-87. [PMID: 25343670 DOI: 10.2217/bmm.14.20] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]